Nuvilex Applies in Australia for the Orphan Drug

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Nuvilex Applies in Australia for the Orphan Drug Designation for Pancreatic Cancer Treatment

SILVER SPRING, Md., Nov. 7, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it has submitted, through its subsidiary Nuvilex Australia, an application to the Therapeutic Goods Administration (TGA) in Australia to obtain the Orphan Drug Designation for its pancreatic cancer treatment. This submission follows similar applications to the United States Food and Drug Administration and the European Medicines Agency in the European Union (EU). Like those in the U.S. (7 years) and the EU (10 years), granting of the Orphan Drug Designation carries with it a significant period of marketing exclusivity. In Australia this period is 5 years.

Nuvilex's CEO and President, Kenneth L. Waggoner, commented, "The application for the Orphan Drug Designation in Australia is the third such application made to the drug regulatory authorities in major areas of the world. In order for the Orphan Drug Designation to be granted to a particular drug or treatment, the target disease must be considered life-threatening and 'rare.' Pancreatic cancer, no matter where it occurs in the world, is undoubtedly life-threatening and, in our opinion, its prevalence in Australia classifies it as a rare disease. It is expected that this application to the TGA will be reviewed relatively quickly, and we may have a decision on it before the end of the year."

Nuvilex's pancreatic cancer treatment consists of implanting living cells that have been encapsulated in pin-head sized, cellulose-based, protective "cocoons" through the use of the proprietary Cell-in-a-Box ® technology, followed by the administration of low doses of the anticancer prodrug ifosfamide. Ifosfamide is a drug that must be converted into its "cancer-killing" form for it to be effective. The cells that are encapsulated are efficient and effective at carrying out this conversion. By placing these encapsulated ifosfamide-activating cells in proximity to the pancreatic cancer, the anticancer effects of the drug are optimized. In addition, as shown in early-phase clinical trials, because low doses of the anticancer drug are used the side effects from it are greatly reduced in severity and the treatment is well tolerated by the patients undergoing this novel treatment.

Mr. Waggoner continued, "As with the applications for the Orphan Drug Designation in the U.S. and the EU, we are extremely grateful to our colleagues at Clinical Network Services (CNS) for their assistance in the preparation of this Australian submission. In particular, the services of Dr. Natalie Thomas in the preparation and submission of this application were invaluable. CNS, one of Australia's leading Contract Research Organizations, has been contracted by Nuvilex to conduct its Phase 2b pancreatic cancer clinical trial in that country."

About Nuvilex

Nuvilex (OTCQB:NVLX) is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box ® . This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. Nuvilex's treatment for pancreatic cancer involves the well-known anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or "cancer-killing" form. Nuvilex is also working toward improving the quality of life for patients with advanced pancreatic cancer and on treatments for other types of solid cancerous tumors. In addition, Nuvilex is developing treatments for cancer based upon chemical constituents of marijuana known as cannabinoids. Nuvilex is examining ways to exploit the benefits of Cell-in-a-Box ® technology in optimizing the anticancer effectiveness of such cannabinoids against cancers, while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments. This provides Nuvilex a unique opportunity to develop "green" approaches to fighting deadly cancers, such as those of the pancreas, brain and breast, which affect hundreds of thousands of individuals worldwide every year.

Safe Harbor

This press release may contain forward-looking statements regarding Nuvilex and its future events and results that involve inherent risks and uncertainties. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to Nuvilex or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of Nuvilex, that could cause actual results to differ materially from those set forth in the forward-looking statements include Nuvilex's ability to continue as a going concern, delays or unsuccessful results in clinical trials or flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of Nuvilex's intellectual property and Nuvilex's continued ability to raise capital. Nuvilex does not assume any obligation to update any of these forward-looking statements.

More information about Nuvilex can be found at www.nuvilex.com . It can also be obtained by contacting Investor Relations.

Investor Relations Contacts: Clare Matschullat Blueprint Life Science Group Telephone: 415.375.3340 Ext. 106

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Red Cat Stock Drama: Revenue Targets and Legal Waves

Updated Category News Views 221

Red Cat's Revenue Predictions Crash and Burn Sitting there on August 6, 2026, Red Cat Holdings had everyone believing they were on a fast track to hitting a hefty revenue target: $150–$180 million for FY2026. CEO Jeffrey Thompson didn't mince words, boasting confidence like a captain before a storm. Fast forward three months, and they're waving the white flag, tossing...

Continue Reading
ZAKSIMLAB Tests Kombucha and Salmon Snack Pairing in Cafes

Updated Category News Views 181

A fish-based chip beside a fizzy tea mix is an odd little commercial wager, and that is exactly why ZAKSIMLAB's latest move deserves a look. The Seoul food brand launched Salmon Crunch Protein Chips in September, then put the snack next to its powdered kombucha at the 2026 Cafe & Bakery Fair Season 2. This is not a grand earnings story; no sales, pricing, store-count, or...

Continue Reading
illumine Targets Childcare Chain Control and Risk Gaps

Updated Category News Views 52

Expansion Gets Messy Before It Gets Impressive Childcare operators do not usually stumble because they forgot how to care for children; they stumble because the back office fractures as the network grows. One center handles fees one way, another lets enrollment leads work a different funnel, and headquarters discovers too late that its reports are arguing with each other....

Continue Reading
Albany Masonry Waterproofing Is a Quiet Value Play

Updated Category News Views 59

Winter works its mischief one soaked brick at a time. That is the unglamorous truth behind Sean Mulligan's discussion of masonry waterproofing for Albany-area homes. Brick and stone look tough enough to outlast the furniture, the siding, maybe the whole neighborhood. Yet they are porous materials, and in a region where rain, snowmelt, and sharp temperature swings keep...

Continue Reading
Ideas Abu Dhabi Puts Water Innovation on Stage

Updated Category News Views 75

Water rarely gets the spotlight until a pipe fails, a harvest shrinks, or a city starts rationing. That is why the agenda around Ideas Abu Dhabi at the 2026 UN Water Conference deserves more than the usual polite nod given to conference programming. From 7 to 10 December in Abu Dhabi, this is shaping up as a public-facing attempt to connect a hard physical problem with...

Continue Reading
DocLinq Takes Aim at Care Gaps Between Office Visits

Updated Category News Views 48

Healthcare's most expensive loose ends often pile up after the appointment ends. DocLinq, launched from Columbia, Maryland, is taking a run at that awkward stretch between office visits, where records sit in separate systems, chronic-care follow-up gets uneven, and patients are expected to remember far more than any human reasonably can. This is not a story about AI...

Continue Reading
Trucking Hub Bets on Faster MVR Checks Nationwide Today

Updated Category News Views 98

Driver paperwork is where plenty of supposedly modern fleet systems still go to die. Trucking Hub’s Nov. 18 launch of GetMVR.com takes a clean swing at that mess: an online platform for ordering Motor Vehicle Records in all 50 states, with instant reports available in 48. It is not glamorous software, and frankly that is why it may matter. Fleets do not lose sleep over...

Continue Reading
Kyndryl's Gartner Sweep Raises the Execution Bar Again

Updated Category News Views 32

A workplace help-desk ticket may sound dull as drywall, but at a giant enterprise it can become a very expensive little failure. That is why Kyndryl's latest Gartner recognition deserves more than the usual corporate backslapping. The company was named a Leader in Gartner's 2026 Magic Quadrant for Outsourced Digital Workplace Services for a third consecutive year, and...

Continue Reading
Four Pending Deals Put Shareholder Terms Under Scrutiny

Updated Category News Views 101

Four corporate transactions landed under a legal microscope on November 18, and that is never background noise for shareholders trying to judge whether the paperwork matches the price. Halper Sadeh LLC says it is investigating proposed deals involving WaFd, Personalis, Dana and Baldwin Group for possible federal securities-law violations and/or fiduciary-duty breaches....

Continue Reading
Floating Solar Gets a Serious Test in Central New York

Updated Category News Views 185

A flooded quarry pit outside Cortlandville is getting a second career, and that is more interesting than another solar announcement draped across empty acreage. Third Pillar Power has started construction on Crown City Solar at Suit-Kote Corporation's active Polkville Crushed Stone Facility, pairing a working mine, asphalt plant, and storage terminal with what the...

Continue Reading

Top 5 Most Recently Viewed Articles

Spotlighting Canada's Culinary Gems with Air Canada's 2024 List

Updated Category News Views 134

Air Canada Announces the 2024 Best New Restaurants Longlist Air Canada has named its Best New Restaurants 2024 longlist, spotlighting 30 standout places to eat from 18 cities. It’s a snapshot of how wide and inventive Canada’s dining scene has become—different regions, different voices, one lively table. What Sets This List Apart Launched in 2002, Best New...

Continue Reading
Investors Retain $7.7 Trillion in Money-Market Funds Amid Shifts

Updated Category News Views 335

Investors Retain $7.7 Trillion in Money-Market Funds Amid Shifts US investors continue to firmly hold a record $7.7 trillion in money-market funds, with little inclination to move these funds elsewhere. This situation reflects a significant confidence in the safety of these investments. Record Highs in Money-Market Fund Assets The assets contained within money-market...

Continue Reading
Understanding the Stabilisation Options for DEC Shares

Updated Category News Views 167

Diversified Energy Company PLC Stabilisation Notice Overview The announcement from Diversified Energy Company PLC (LSE: DEC, NYSE: DEC) includes critical information pertinent to investors in its shares. It emphasizes that neither the announcement nor its contents should serve as a basis for reliance in any jurisdiction regarding offers or commitments concerning the...

Continue Reading
Ontex Sells Turkish Subsidiary to Dilek Grup for Future Growth

Updated Category News Views 286

Ontex Agrees to Sell Turkish Subsidiary Ontex Group NV [EURONEXT: ONTEX], recognized as a prominent developer and producer in the personal care sector, has confirmed a significant decision to sell its Turkish subsidiary to Dilek Grup. This move is not just a transaction; it's a part of Ontex's broader strategy to focus more intently on retail and healthcare markets across...

Continue Reading
707 Cayman Holdings Partners with Precious Choice for Crypto

Updated Category News Views 440

707 Cayman Holdings Limited and Precious Choice Alliance 707 Cayman Holdings Limited (NASDAQ: JEM), a prominent company in Hong Kong dedicated to quality apparel and comprehensive supply chain management, has taken an exciting step forward by announcing a partnership with Precious Choice Global Limited. This strategic collaboration marks a pivotal moment for both entities...

Continue Reading